PMGC Holdings Inc. (NASDAQ:ELAB) shares are trading higher on Friday as the company is advancing its engineered probiotic platform.
Details
PMGC Holdings’ subsidiary NorthStrive Biosciences Inc. announced plans to initiate an independent flow cytometry study to further characterize its engineered probiotic candidate, EL-22.
This study aims to quantify myostatin antigen expression on Lactobacillus casei, which is designed to help preserve muscle during weight loss treatments, including those involving GLP-1 receptor agonists.
The independent analysis will support comparability against materials previously manufactured by MOA Life Plus Co. Ltd., enhancing product identity and manufacturing consistency for EL-22.
Company Context
PMGC Holdings is advancing in Medical Aesthetics and Biopharmaceutical Innovation, specializing in Skin Aesthetics, Obesity, and Metabolic Health. The company’s focus on engineered probiotics, particularly through its EL-22 platform, positions it uniquely in the biopharmaceutical space, targeting significant health issues like muscle preservation during weight loss.
Recent developments in product characterization and manufacturing consistency are crucial for PMGC Holdings as it seeks to enhance its market position and meet regulatory standards. This strategic focus on innovation could drive future growth and investor interest.
PMGC Holdings (ELAB) Business Overview And EL-22 Platform
ELAB Stock Price Activity: PMGC Holdings shares were up 14.06% at $1.20 at the time of publication on Friday, according to Benzinga Pro data.
Photo via Shutterstock
